Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
July 23 2020 - 4:15PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT
on Thursday, August 6, 2020, following the release of its second
quarter 2020 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or
1-201-689-8354 (international). Please dial in at least 10 minutes
in advance and inform the operator that you would like to join the
“Puma Biotechnology Conference Call.” A live webcast of the
conference call and presentation slides may be accessed on the
Investors section of the Puma Biotechnology website at
http://www.pumabiotechnology.com. A replay of the call will be
available shortly after completion of the call and will be archived
on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licenses the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in 2017 for
the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also
approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic
HER2-positive breast cancer who have received two or more prior
anti-HER2-based regimens in the metastatic setting. NERLYNX was
granted marketing authorization by the European Commission in 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at
www.pumabiotechnology.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200723005170/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024